


Bölüm 27

Pankreas Cerrahisinin Endokrin Komplikasyonları ve Yönetimi



Ali Kemal KAYAPINAR¹

Endokrin pankreas

Endokrin hücreler pankreas boyunca dağılmış adacıklar şeklindeki (langerhans) kümelerden oluşur. Sağlıklı bir kişide pankreas hacminin %2-3'ünü yaklaşık bir milyon langerhans adacığı oluşturur. Her adacık insülin üreten beta (β), glukagon üreten alfa (α), somatostatin üreten delta (δ), grelin üreten gama (γ) ve pankreas polipeptit (PP) üreten hücrelerinden oluşmaktadır (1).

İnsülin

İnsülin pankreas boyunca beta hücreleri tarafından sentezlenen ve 51 aminoasitlik bir peptittir. İnsülin glikoz seviyesini glukagon, glikojenoliz ve glukoneogenez inhibisyonu gibi etkileri ile düzenler. İnsülin adipoz doku ve kas içine glikoz transferini arttırarak bu dokuda glikojen sentezini arttırmaktadır (2,3).

Glukagon

Glukagon ağırlıklı olarak pankreasın gövde ve kuyruğunda yer alan ve alfa hücrelerinde proglukagondan sentezlenen 29 aminoasitlik bir peptittir (4). Glukagon insülin ve somatostatin sekresyonunu uyarmasına ek olarak hepatik glukoz-

¹ Op. Dr., Sağlık Bilimleri Üniversitesi İzmir Tepecik Eğitim ve Araştırma Hastanesi, Gastroenteroloji Cerrahi, alikemalkayapinar@gmail.com

KAYNAKLAR

1. Bonner-Weir, S. (1991). Anatomy of the islet of Langerhans. In: Samols E (ed.), *The endocrine pancreas* (15-27), New York: Raven Press.
2. Ramnanan CJ, Edgerton DS, Rivera N, et al Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. *Diabetes*. 2010;59(6):1302–1311.
3. Kahn BB. Glucose transport: pivotal step in insulin action. *Diabetes*. 1996;45(11):1644–1654.
4. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. *World J Surg*. 2001;25(4):452–460.
5. Klover PJ, Mooney RA. Hepatocytes: critical for glucose homeostasis. *Int J Biochem Cell Biol*. 2004;36(5):753–758.
6. Reichlin S. Somatostatin (second of two parts). *N Engl J Med*. 1983; 309(25):1556–1563.
7. Beglinger C, Drewe J. Somatostatin and octreotide: physiological background and pharmacological application. *Digestion*. 1999;60(Suppl 2):2–8.
8. Paye F. The Pancreatic stump after pancreatoduodenectomy:the 'Achilles heel' revisited. *J. Visc.Surg*. 2010;147:e13–e20
9. Wang X, Misawa R, Zielinski MC, et al. Regional differences in islet distribution in the human pancreas-preferential beta-cell loss in the head region in patients with type 2 diabetes. *PloS one*. 2013;8(6):e67454.
10. Mezza T, Cefalo CM, Cinti F, et al. Endocrine and metabolic insights from pancreatic surgery. *Trends in Endocrinology & Metabolism*. 2020; 31(10):760-772.
11. W L, Nahm CB, Jamieson NB, et al. Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: a systematic review. *Clinical endocrinology*. 2020;92(5):396-406.
12. Leahy JL, Bumbalo LM, Chen C, et al. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomies diabetic rats. *Diabetes*. 1994;43:173–179
13. Liu YQ, Nevin PW, Leahy JL. β -Cell adaptation in 60% pancreatectomy rats that preserves normoinsulinemia and normoglycemia. *American Journal of Physiology-Endocrinology And Metabolism*. 2000;279(1):E68-E73.
14. Kendall DM, Sutherland DE, Najarian JS, et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. *New England Journal of Medicine*. 1990;322(13):898-903.
15. King J, Kazanjian K, Matsumoto J, et al. Distal pancreatectomy: incidence of postoperative diabetes. *Journal of Gastrointestinal Surgery*. 2008;12(9):1548-1553.
16. Büchler MW, Friess H, Bittner R, et al. Duodenum-preserving pancreatic head resection: long-term results. *Journal of Gastrointestinal Surgery*. 1997;1(1):13-19.
17. Büchler MW, Friess H, Müller MW, et al. Randomized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. *The American journal of surgery*. 1995;169(1):65-70.
18. Mezza T, Sorice GP, Conte C, et al. β -Cell glucose sensitivity is linked to insulin/glucagon bihormonal cells in nondiabetic humans. *The Journal of Clinical Endocrinology & Metabolism*. 2016;101(2):470-475.
19. American Diabetes Association. 2. Classification and diagnosis of diabetes. *Diabetes care*. 2017; 40(Supplement 1):S11-S24.

20. Hardt PD, Brendel MD, Kloer HU, et al. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? *Diabetes Care*. 2008;31(Suppl 2):S165-169.
21. Schrader H, Menge BA, Breuer TG, et al. Impaired glucose-induced glucagon suppression after partial pancreatectomy. *J Clin Endocrinol Metab*. 2009;94(8):2857-2863.
22. Lee BW, Kang HW, Heo JS, et al. Insulin secretory defect plays a major role in the development of diabetes in patients with distal pancreatectomy. *Metab Clin Exp*. 2006;55(1):135-141.
23. Muscogiuri G, Mezza T, Prioletta A, et al. Removal of duodenum elicits GLP-1 secretion. *Diabetes Care*. 2013;36(6):1641-1646.
24. Kang JS, Jang JY, Kang MJ, et al. Endocrine function impairment after distal pancreatectomy: incidence and related factors. *World J Surg*. 2016;40(2):440-446.
25. Kwon JH, Kim SC, Shim IK, et al. Factors affecting the development of diabetes mellitus after pancreatic resection. *Pancreas*. 2015;44(8):1296-1303
26. Shirakawa S, Matsumoto I, Toyama H, et al. Pancreatic volumetric assessment as a predictor of new-onset diabetes following distal pancreatectomy. *J Gastrointest Surg*. 2012;16(12):2212-2219.
27. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabet Med*. 2013;30(7):803-817.
28. Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. *Diabetes Ther*. 2017;8(3):475-487.
29. Muller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? *Ann Surg*. 2007;246(6):966-974 discussion 74-5.
30. Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. *J Gastrointest Surg*. 2007;11(2):209-216.
31. Maker AV, Sheikh R, Bhagia V. Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia. *Langenbeck's archives of surgery*. 2017;402(6):873-883.
32. Blanchet MC, Andreelli F, Scoazec JY, et al. Total pancreatectomy for mucinous pancreatic tumor. *Ann Chir*. 2002;127(6):439-448.
33. Sauvanet A. Intraductal papillary mucinous neoplasms of the pancreas: indication, extent, and results of surgery. *Surg Oncol Clin N Am*. 2008; 17(3):587-606 ix.
34. Yamaguchi K, Konomi H, Kobayashi K, et al. Total pancreatectomy for intraductal papillary-mucinous tumor of the pancreas: reappraisal of total pancreatectomy. *Hepato-Gastroenterology*. 2005;52(65):1585-1590.
35. Zerbi A, Ortolano E, Balzano G, et al. Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? *Ann Surg Oncol*. 2008;15(4):1161-1168.
36. Del Chiaro M, Zerbi A, Capurso G, et al. Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. *Dig Liver Dis*. 2010;42(9):597-605.
37. Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? *J Gastrointest Surg*. 2005;9(8):1059-1066
38. Dresler CM, Fortner JG, McDermott K, et al. Metabolic consequences of (regional) total pancreatectomy. *Ann Surg*. 1991;214(2):131-140.

39. Casadei R, Ricci C, Monari F, et al. Clinical outcome of patients who underwent total pancreatectomy. *Pancreas*. 2010;39(4):546–547.
40. Parsaik AK, Murad MH, Sathananthan A, et al. Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. *Clin Endocrinol*. 2010;73(6):723–731.
41. Jaleel A, Halvatsiotis P, Williamson B, et al. Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. *Diabetes Care*. 2005;28(3):645–65.
42. Munoz M, Pronovost P, Dintzis J, et al.. Implementing and evaluating a multicomponent inpatient diabetes management program: putting research into practice. *The Joint Commission Journal on Quality and Patient Safety*. 2012;38(5):195-AP4.
43. Christopher DS, Rita RK, Frederick L (2011). *Johns Hopkins Poc-It Center Diabetes Guide 2012* (1st edition). Montgomery; Jones & Bartlett Learning
44. Bolli GB, Andreoli AM, Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. *Diabetes Technol Ther*. 2011;13(Suppl 1):S43–S52.
45. Schmeltz LR, DeSantis AJ, Thiyagarajan V, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. *Diabetes Care*. 2007;30(4):823–828.
46. Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. *J Diabetes Sci Technol*. 2010;4(5):1174–1181
47. Okabayashi T, Nishimori I, Yamashita K, et al. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. *Arch Surg*. 2009;144(10):933–937.
48. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. *Diabetes Care*. 2002;25(3):593–98
49. Bertuzzi F, Secchi A, Di Carlo V. Islet transplantation in type 1 diabetic patients. *Transplant Proc*. 2004;36(3):603–604.
50. Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. *Diabetes Care*. 2016; 39(7):1230–1240.
51. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. *N Engl J Med*. 2006; 355(13):1318–1330.